HD
"Could tell me any good reason (top of prescribers' habit and pharmacy "ignorance" why is L still sold?"
Let me give this a try. The first reason it is still sold is the reason you have given earlier. These primaries and cards have been prescribing it for awhile and know how to write the script. Say I am a PCP and I am use to prescribing Vicodin, I know what dose to put down. Now someone says Percocet is better(just an example)..I don't know the dose and have to look it up..(3 minutes on the computer)..am I going to do it...maybe not..do not underestimate the power of laziness.
Reason two...Drug reps...The L. reps are not operating under the pressure of the V reps, because all they have to do is "hold serve". The V reps have to give clear reasons to change. The L reps are clever, they take Amarin's arguments and twist them back against V. How so? Well, they say in L. you get the DHA your body needs for cognitive function, and DHA lowers trigs more than EPA does. The doctors do not not the anti inflammatory argument, and I guess this is why the company should be planning a strategy involving freedom of speech.
What Amarin needs to tell the doctors...
CVD is caused by inflammation..Rational treatment should include treating the inflammation. Scientific evidence supports the fact EPA lowers systemic inflammation and direct observation on arterial lesions shows EPA will increase vessel lumen area in atherosclerotic blood vessels and stabilize atherosclerotic plaques which cause AMIs and thrombotic strokes.
JELIS lowered CVD events by 20% in a population much more stable than middle aged americans. The percentage CVD lowering was the same for major and minor coronary events. In the mixed dyslipidemia sub set, the drug lowered CVD events 53%.
Lovaza is not a substitute for Vascepa. EPA's effects are dose dependent and therapeutic efficacy is related to absolute EPA levels and the AA/EPA ratio. This is born out by large scale population studies.
":>) JL
